Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Drug Development
608 Articles Available
1
26
Can't find what you're looking for? Try our
advanced search
.
Preclinical
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
PAO-11-20-CL-01
The Future of Healthcare
How Does Polpharma Biologics Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-010
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
PAP-Q4-20-NI-007
Gene Therapy
Anticipating the Next Decade of Gene Therapy
PAO-11-20-CL-02
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
PAP-Q3-20-CL-004
Lipid Excipients
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strategies
PAP-Q3-20-CL-024
Organ-on-a-Chip
Organ-on-a-Chip Technology Aims to Disrupt Traditional Drug Testing Models
PAP-Q3-20-CL-014
The Future of Healthcare
How Is Polpharma Biologics Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-007
Microphysiological Systems
Accelerating Drug Development with Microphysiological Systems (MPS)
PAP-Q3-20-CL-003
Endocannabinoid System
Realizing the Promise of Therapeutics Targeting the Endocannabinoid System
PAP-Q3-20-CL-005
Roundtable
Q: What steps is your company taking to address drug pricing issues?
PAP-Q3-20-NI-008
Drug Development
Alaxia Breaks New Ground With Lead Compound ALX‑009 as Virucidal Agent
PR-M09-20-24
Migraines
REYVOW Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase Study
PR-M09-20-22
Clinical Results
AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients
PR-M07-20-NI-027
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M07-20-NI-015
Capacity Expansion
Vetter Further Expands its Development Service with New Site in Austria
PR-M07-20-NI-010
Chronokines
Delivering Breakthrough Medicines for Rare Hematologic Diseases and Cancers
PAP-Q2-20-CL-003
Antibody–Drug Conjugates
Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life
PAP-Q2-20-CL-012
Chronokines
Solving Unmet Clinical Needs by Harnessing the Science of Aging
PAP-Q2-20-CL-013
Cancer Therapies
Computational Discoveries for Clinical Development of Novel Cancer Therapies
PAP-Q2-20-CL-014
Drug Repositioning
A Therapeutic Strategy for Neurological Disorders
PAP-Q2-20-CL-016
Immunotherapy
Leveraging the Native Immune Response to Fight Cancer
PAP-Q2-20-CL-017
Novel Antibiotics
Applying a Synthetic Approach to the Development of a New Generation of Antibiotics
PAP-Q2-20-CL-019
In Conversation
In Conversation: Novel Off-The-Shelf Targeted Cell Therapies
PAP-Q2-20-CL-021
1
26
»
